FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:841-847 September 19, 1996 Number 12 Next

	Full Text PDF Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Inhaled -agonists are the most commonly used treatment for asthma, but data suggest that regularly scheduled use of these agents may have a deleterious effect on the control of asthma. We compared the effects of regularly scheduled use of inhaled albuterol with those of albuterol used only as needed in patients with mild chronic, stable asthma.

Methods In a multicenter, double-blind study, we randomly assigned 255 patients with mild asthma to inhale albuterol either on a regular schedule (126 patients) or only as needed (129 patients). The patients were followed for 16 weeks.

Results The primary outcome indicator, peak expiratory air flow measured in the morning, did not change significantly during the treatment period in the scheduled (416 liters per minute after the run-in period and 414 liters per minute after the treatment period) or the as-needed (424 liters per minute at both times) treatment groups (P = 0.71). There were no significant differences between the two groups in peak flow variability, forced expiratory volume in one second, the number of puffs of supplemental albuterol needed, asthma symptoms, asthma quality-of-life score, or airway responsiveness to methacholine. The statistically significant differences between the groups in evening peak flow and in the short-term bronchodilator response to inhaled albuterol were small and judged to be clinically unimportant.

Conclusions In patients with mild asthma, neither deleterious nor beneficial effects derived from the regular use of inhaled albuterol beyond those derived from use of the drug as needed. Inhaled albuterol should be prescribed for patients with mild asthma on an as-needed basis.

Source Information

From Brigham and Women's Hospital and Harvard Medical School, Boston (J.M.D., E.I.); the University of California at San Francisco, San Francisco (H.A.B., J.V.F., S.C.L.); Milton S. Hershey Medical Center, Hershey, Pa. (V.M.C.); Thomas Jefferson University, Philadelphia (J.E.F., S.P.P.); the University of Wisconsin, Madison (R.F.L., C.S.); and the National Jewish Center for Immunology and Respiratory Medicine, Denver (R.J.M., S.J.S.). Additional contributing authors were Reuben Cherniack, M.D. (National Jewish Center for Immunology and Respiratory Medicine, Denver), and Suzanne Hurd, Ph.D. (National Heart, Lung, and Blood Institute, Bethesda, Md.).

Address reprint requests to Dr. Drazen at the Respiratory Disease Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115.

Full Text of this Article

Related Letters:

Albuterol in Mild Asthma
Suissa S., Ernst P., Zahger D., Drazen J. M., Israel E., The National Heart, Lung, and Blood Institute's Asthma Clinical Research Network
Extract | Full Text  
N Engl J Med 1997; 336:729-730, Mar 6, 1997. Correspondence

Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma
FitzGerald J. M., Salvi S., Pauwels R. A., Tattersfield A. E., Löfdahl C.-G.
Extract | Full Text  
N Engl J Med 1998; 338:1071-1073, Apr 9, 1998. Correspondence

This article has been cited by other articles:

• Papi, A., Canonica, G. W., Maestrelli, P., Paggiaro, P., Olivieri, D., Pozzi, E., Crimi, N., Vignola, A. M., Morelli, P., Nicolini, G., Fabbri, L. M., the BEST Study Group, (2007). Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma. NEJM 356: 2040-2052 [Abstract] [Full Text]  
• Ameredes, B. T., Calhoun, W. J. (2006). (R)-Albuterol for Asthma: Pro [a.k.a. (S)-Albuterol for Asthma: Con].. Am. J. Respir. Crit. Care Med. 174: 965-969 [Full Text]  
• Barnes, P. J. (2006). Treatment with (R)-Albuterol Has No Advantage over Racemic Albuterol.. Am. J. Respir. Crit. Care Med. 174: 969-972 [Full Text]  
• Barnes, P. J. (2006). Rebuttal by Dr. Barnes. Am. J. Respir. Crit. Care Med. 174: 974-974 [Full Text]  
• Wechsler, M. E., Lehman, E., Lazarus, S. C., Lemanske, R. F. Jr., Boushey, H. A., Deykin, A., Fahy, J. V., Sorkness, C. A., Chinchilli, V. M., Craig, T. J., DiMango, E., Kraft, M., Leone, F., Martin, R. J., Peters, S. P., Szefler, S. J., Liu, W., Israel, E., for the National Heart Lung and Blood Institute's, (2006). beta-Adrenergic Receptor Polymorphisms and Response to Salmeterol. Am. J. Respir. Crit. Care Med. 173: 519-526 [Abstract] [Full Text]  
• Kelly, H W. (2005). What Is New with the {beta}2-Agonists: Issues in the Management of Asthma. The Annals of Pharmacotherapy 39: 931-938 [Abstract] [Full Text]  
• Boushey, H. A., Sorkness, C. A., King, T. S., Sullivan, S. D., Fahy, J. V., Lazarus, S. C., Chinchilli, V. M., Craig, T. J., Dimango, E. A., Deykin, A., Fagan, J. K., Fish, J. E., Ford, J. G., Kraft, M., Lemanske, R. F. Jr., Leone, F. T., Martin, R. J., Mauger, E. A., Pesola, G. R., Peters, S. P., Rollings, N. J., Szefler, S. J., Wechsler, M. E., Israel, E., the National Heart, Lung, and Blood Institute's As, (2005). Daily versus As-Needed Corticosteroids for Mild Persistent Asthma. NEJM 352: 1519-1528 [Abstract] [Full Text]  
• D'Alonzo, G. E. Jr. (2004). Levalbuterol in the Treatment of Patients With Asthma and Chronic Obstructive Lung Disease. JAOA: Journal of the American Osteopathic Association 104: 288-293 [Abstract] [Full Text]  
• Callaerts-Vegh, Z., Evans, K. L. J., Dudekula, N., Cuba, D., Knoll, B. J., Callaerts, P. F. K., Giles, H., Shardonofsky, F. R., Bond, R. A. (2004). Effects of acute and chronic administration of {beta}-adrenoceptor ligands on airway function in a murine model of asthma. Proc. Natl. Acad. Sci. USA 101: 4948-4953 [Abstract] [Full Text]  
• Wraight, J.M., Hancox, R.J., Herbison, G.P., Cowan, J.O., Flannery, E.M., Taylor, D.R. (2003). Bronchodilator tolerance: the impact of increasing bronchoconstriction. Eur Respir J 21: 810-815 [Abstract] [Full Text]  
• Palmer, L. J., Silverman, E. S., Weiss, S. T., Drazen, J. M. (2002). Pharmacogenetics of Asthma. Am. J. Respir. Crit. Care Med. 165: 861-866 [Full Text]  
• Douma, W. R., Kerstjens, H. A. M., de Gooijer, A., Overbeek, S. E., Koeter, G. H., Postma, D. S. (2002). Initial Improvements in Lung Function and Bronchial Hyperresponsiveness Are Maintained During 5 Years of Treatment With Inhaled Beclomethasone Dipropionate and Terbutaline. Chest 121: 151-157 [Abstract] [Full Text]  
• Cates, C. (2001). Extracts from ""Clinical Evidence"": Chronic asthma. BMJ 323: 976-979 [Full Text]  
• Naureckas, E. T., Solway, J. (2001). Mild Asthma. NEJM 345: 1257-1262 [Full Text]  
• O'BYRNE, P. M., BARNES, P. J., RODRIGUEZ-ROISIN, R., RUNNERSTROM, E., SANDSTROM, T., SVENSSON, K., TATTERSFIELD, A. (2001). Low Dose Inhaled Budesonide and Formoterol in Mild Persistent Asthma . The OPTIMA Randomized Trial. Am. J. Respir. Crit. Care Med. 164: 1392-1397 [Abstract] [Full Text]  
• Lemanske, R. F. Jr, Sorkness, C. A., Mauger, E. A., Lazarus, S. C., Boushey, H. A., Fahy, J. V., Drazen, J. M., Chinchilli, V. M., Craig, T., Fish, J. E., Ford, J. G., Israel, E., Kraft, M., Martin, R. J., Nachman, S. A., Peters, S. P., Spahn, J. D., Szefler, S. J., for the Asthma Clinical Research Network of the Na, (2001). Inhaled Corticosteroid Reduction and Elimination in Patients With Persistent Asthma Receiving Salmeterol: A Randomized Controlled Trial. JAMA 285: 2594-2603 [Abstract] [Full Text]  
• Sears, M. R. (2001). Deleterious Effects of Inhaled {beta}-Agonists : Short-Acting and Long-Acting Agents Differ. Chest 119: 1297-1299 [Full Text]  
• FAHY, J. V., BOUSHEY, H. A., LAZARUS, S. C., MAUGER, E. A., CHERNIACK, R. M., CHINCHILLI, V. M., CRAIG, T. J., DRAZEN, J. M., FORD, J. G., FISH, J. E., ISRAEL, E., KRAFT, M., LEMANSKE, R. F., MARTIN, R. J., McLEAN, D., PETERS, S. P., SORKNESS, C., SZEFLER, S. J. (2001). Safety and Reproducibility of Sputum Induction in Asthmatic Subjects in a Multicenter Study. Am. J. Respir. Crit. Care Med. 163: 1470-1475 [Abstract] [Full Text]  
• Bourdet, S. V., Williams, D. (2001). Management Considerations for Chronic Asthma. Journal of Pharmacy Practice 14: 108-125 [Abstract]  
• Leone, F. T., Mauger, E. A., Peters, S. P., Chinchilli, V. M., Fish, J. E., Boushey, H. A., Cherniack, R. M., Drazen, J. M., Fahy, J. V., Ford, J., Israel, E., Lazarus, S. C., Lemanske, R. F., Martin, R. J., McGeady, S. J., Sorkness, C., Szefler, S. J. (2001). The Utility of Peak Flow, Symptom Scores, and {beta}-Agonist Use as Outcome Measures in Asthma Clinical Research. Chest 119: 1027-1033 [Abstract] [Full Text]  
• MOY, M. L., ISRAEL, E., WEISS, S. T., JUNIPER, E. F., DUBÉ, L., DRAZEN, J. M., the NHLBI Asthma Clinical Rese, (2001). Clinical Predictors of Health-related Quality of Life Depend on Asthma Severity. Am. J. Respir. Crit. Care Med. 163: 924-929 [Abstract] [Full Text]  
• Anthonisen, N. (2001). Guidelines do matter. CMAJ 164: 641-642 [Full Text]  
• Boulet, L.-P., Cockcroft, D. W., Speir, W. A. Jr (2001). Regularly Scheduled Inhaled Bronchodilators and Maintenance Asthma Therapy. Chest 119: 987-988 [Full Text]  
• COOK, D., GUYATT, G., WONG, E., GOLDSTEIN, R., BEDARD, M., AUSTIN, P., RAMSDALE, H., JAESCHKE, R., SEARS, M. (2001). Regular Versus As-Needed Short-Acting Inhaled {beta}-Agonist Therapy for Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 163: 85-90 [Abstract] [Full Text]  
• Shapiro, G., Bronsky, E., Murray, A., Barnhart, F., VanderMeer, A., Reisner, C. (2000). Clinical Comparability of Ventolin Formulated With Hydrofluoroalkane or Conventional Chlorofluorocarbon Propellants in Children With Asthma. Arch Pediatr Adolesc Med 154: 1219-1225 [Abstract] [Full Text]  
• Busse, W. W. (2000). A 47-Year-Old Woman With Severe Asthma. JAMA 284: 2225-2233 [Full Text]  
• Drysdale, C. M., McGraw, D. W., Stack, C. B., Stephens, J. C., Judson, R. S., Nandabalan, K., Arnold, K., Ruano, G., Liggett, S. B. (2000). Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. USA 97: 10483-10488 [Abstract] [Full Text]  
• Reicin, A., White, R., Weinstein, S. F., Finn, A. F. Jr, Nguyen, H., Peszek, I., Geissler, L., Seidenberg, B. C., for the Montelukast/Loratadine Study Group, (2000). Montelukast, a Leukotriene Receptor Antagonist, in Combination With Loratadine, a Histamine Receptor Antagonist, in the Treatment of Chronic Asthma. Arch Intern Med 160: 2481-2488 [Abstract] [Full Text]  
• ISRAEL, E., DRAZEN, J. M., LIGGETT, S. B., BOUSHEY, H. A., CHERNIACK, R. M., CHINCHILLI, V. M., COOPER, D. M., FAHY, J. V., FISH, J. E., FORD, J. G., KRAFT, M., KUNSELMAN, S., LAZARUS, S. C., LEMANSKE, R. F. Jr., MARTIN, R. J., MCLEAN, D. E., PETERS, S. P., SILVERMAN, E. K., SORKNESS, C. A., SZEFLER, S. J., WEISS, S. T., YANDAVA, C. N. (2000). The Effect of Polymorphisms of the beta 2-Adrenergic Receptor on the Response to Regular Use of Albuterol in Asthma. Am. J. Respir. Crit. Care Med. 162: 75-80 [Abstract] [Full Text]  
• BOUSQUET, J., JEFFERY, P. K., BUSSE, W. W., JOHNSON, M., VIGNOLA, A. M. (2000). Asthma . From Bronchoconstriction to Airways Inflammation and Remodeling. Am. J. Respir. Crit. Care Med. 161: 1720-1745 [Full Text]  
• (1999). {beta}2-Agonists. CMAJ 161: s28-31 [Full Text]  
• Rosenthal, R. R., Busse, W. W., Kemp, J. P., Baker, J. W., Kalberg, C., Emmett, A., Rickard, K. A. (1999). Effect of Long-term Salmeterol Therapy Compared With As-Needed Albuterol Use on Airway Hyperresponsiveness. Chest 116: 595-602 [Abstract] [Full Text]  
• Hancox, R J, Cowan, J O, Flannery, E M, Herbison, G P, McLachlan, C R, Wong, C S, Taylor, D R (1999). Randomised trial of an inhaled beta 2 agonist, inhaled corticosteroid and their combination in the treatment of asthma. Thorax 54: 482-487 [Abstract] [Full Text]  
• NOCKER, R. E. T., WELLER, F. R., OUT, T. A., de RIEMER, M. J., JANSEN, H. M., van der ZEE, J. S. (1999). A Double-blind Study on the Effect of Inhaled Corticosteroids on Plasma Protein Exudation in Asthma. Am. J. Respir. Crit. Care Med. 159: 1499-1505 [Abstract] [Full Text]  
• Ramsdell, J. W., Klinger, N. M., Ekholm, B. P., Colice, G. L. (1999). Safety of Long-term Treatment With HFA Albuterol. Chest 115: 945-951 [Abstract] [Full Text]  
• Harrison, T W, Oborne, J, Wilding, P J, Tattersfield, A E (1999). Randomised placebo controlled trial of beta  agonist dose reduction in asthma. Thorax 54: 98-102 [Abstract] [Full Text]  
• WALLIN, A., SANDSTRÖM, T., SÖDERBERG, M., HOWARTH, P., LUNDBÄCK, B., DELLA-CIOPPA, G., WILSON, S., JUDD, M., HOLGATE, S., LINDBERG, A., LARSSEN, L., Judd, M., Melander, B. (1999). The Effects of Regular Inhaled Formoterol, Budesonide, and Placebo on Mucosal Inflammation and Clinical Indices in Mild Asthma. Am. J. Respir. Crit. Care Med. 159: 79-86 [Abstract] [Full Text]  
• Wright, R. J, Rodriguez, M., Cohen, S. (1998). Review of psychosocial stress and asthma: an integrated biopsychosocial approach. Thorax 53: 1066-1074 [Full Text]  
• Taylor, D R., Town, G I., Herbison, G P., Boothman-Burrell, D., Flannery, E. M, Hancox, B., Harré, E., Laubscher, K., Linscott, V., Ramsay, C. M, Richards, G. (1998). Asthma control during long term treatment with regular inhaled salbutamol and salmeterol. Thorax 53: 744-752 [Abstract] [Full Text]  
• Nelson, J. A., Strauss, L., Skowronski, M., Ciufo, R., Novak, R., McFadden, E.R. (1998). Effect of Long-Term Salmeterol Treatment on Exercise-Induced Asthma. NEJM 339: 141-146 [Abstract] [Full Text]  
• FitzGerald, J. M., Salvi, S., Pauwels, R. A., Tattersfield, A. E., Lofdahl, C.-G. (1998). Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma. NEJM 338: 1071-1073 [Full Text]  
• Pauwels, R. A., Lofdahl, C.-G., Postma, D. S., Tattersfield, A. E., O'Byrne, P., Barnes, P. J., Ullman, A., The Formoterol and Corticosteroids Establishing Th, (1997). Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma. NEJM 337: 1405-1411 [Abstract] [Full Text]  
• FISH, J. E., PETERS, S. P., CHAMBERS, C. V., MCGEADY, S. J., EPSTEIN, K. R., BOUSHEY, H. A., CHERNIACK, R. M., CHINCHILLI, V. M., DRAZEN, J. M., FAHY, J. V., HURD, S. S., ISRAEL, E., LAZARUS, S. C., LEMANSKE, R. F., MARTIN, R. J., MAUGER, E. A., SORKNESS, C., SZEFLER, S. J., e National Heart, f. t., Lung, , Network, B. I.'s A. C. R. (1997). An Evaluation of Colchicine as an Alternative to Inhaled Corticosteriods in Moderate Asthma. Am. J. Respir. Crit. Care Med. 156: 1165-1171 [Abstract] [Full Text]  
• IRVIN, C. G., MARTIN, R. J., CHINCHILLI, V. M., KUNSELMAN, S. J., CHERNIACK, R. M. (1997). Quality Control of Peak Flow Meters for Multicenter Clinical Trials. Am. J. Respir. Crit. Care Med. 156: 396-402 [Abstract] [Full Text]  
• DRAZEN, J. (1997). Clinical Pharmacology of Leukotriene Receptor Antagonists and 5-Lipoxygenase Inhibitors. Am. J. Respir. Crit. Care Med. 157: 233S-237 [Abstract] [Full Text]  
• Eggleston, P. A. (1997). Are beta -Adrenergic Bronchodilators Safe?. Pediatrics 99: 729-729 [Full Text]  
• Suissa, S., Ernst, P., Zahger, D., Drazen, J. M., Israel, E., The National Heart, Lung, and Blood Institute's As, (1997). Albuterol in Mild Asthma. NEJM 336: 729-730 [Full Text]  
• (1997). Using {beta}2-stimulants in asthma. DTB 35: 1-4 [Abstract] [Full Text]  
• (1996). REGULAR VS. AS-NEEDED ALBUTEROL FOR ASTHMA. JWatch General 1996: 4-4 [Full Text]  
• O'Byrne, P. M., Kerstjens, H. A.M. (1996). Inhaled {beta}2-Agonists in the Treatment of Asthma. NEJM 335: 886-888 [Full Text]